[ad_1]
PEOPLE OF PEOPLE – Cobra Biologics is one of the companies working to make a potential coronavirus vaccine called ChAdOx1 nCoV-19, with scientists at the University of Oxford developing it.
Chief Executive Peter Coleman said the company was not responsible for testing the vaccine’s efficacy, with trials conducted by the Oxford team. Also, there are too many risks involved in the project.
However, he said, if the production process of 200 liters of vaccine for the new coronavirus with the target is completed in mid-May, they will be ready to make 1 million doses per month.
Also read: Kim Jong Un Appears To The Public After Reporting Death, Here’s Trump’s Response
“That is more than enough for clinical trials, but it also has the potential to start supplies for commercial supplies,” Reuters PikirRakyat-Cirebon.com was quoted as saying.
->
He also added that his company could have a capacity of up to two million doses per month.
“The speed at which we operate is much faster than usual. And starting to build batches for commercial supply even before reaching phase one (clinical trials) is very unusual,” he said.
Also Read: China Makes Advanced Tool To Detect Covid-19 Symptoms, Can Measure Temperature Without Contact
British pharmaceutical company AstraZeneca also joined the Oxford vaccine program to develop, produce and distribute potential vaccines to help provide them as soon as possible if they are successful in clinical trials.
